U.S. bonds fell back on Wednesday, as the previous session's stock market rally caused investors' bid for "safe-haven" assets to wane.» Read More
WASHINGTON, Nov 5- The U.S. Supreme Court on Tuesday heard arguments in a case of warring legal doctrines raised by a heart pacemaker patent fight between giant medical devices company Medtronic Inc and privately owned Mirowski Family Ventures LLC.
Westwood Holding Group’s Mark Freeman has investment recommendations for companies less dependent on Fed stimulus.
Oct 25- The U.S. Food and Drug Administration has approved Abbott Laboratories' MitraClip medical device, used to stop heart valve leakage in patients deemed unable to endure valve repair through open heart surgery, the company said on Friday. "We think longer term in the U.S., could be a $500 million product," said RBC Capital Markets analyst Glenn Novarro.
Oct 25- Abbott Laboratories said on Friday that the U.S. Food and Drug Administration approved its MitraClip medical device, used to stop heart valve leakage. A slim majority of advisers to the FDA had recommended approval of the implantable heart device, as some had questioned whether it would be effective for its intended use.
Has Washington distracted you from these money making developments?
Take a look at some of Wednesday's midday movers:
U.S. stock index futures pointed to a higher open on Wednesday, with lawmakers looking to strike a deal to lift the country's borrowing limit before Thursday's deadline.
With a deadline hanging over Congress, stocks could be whipped by headlines from Washington but should ultimately be able to limp through the drama.
On the heels of Microsoft boosting its dividend and renewing its buyback, there are a host of other companies that could be candidates for the same.
We could be witnessing the beginning of a merger wave in biotech, Jim Cramer said Tuesday.
China fined six companies including New Zealand dairy giant Fonterra a total of $110 million following an investigation into price fixing and anti-competitive practices by foreign baby formula makers.
Pfizer reported earnings slightly ahead of forecasts, as the largest U.S. drugmaker lines up a business split that could lead to the spin-off of its generics division.
China is preventing a GlaxoSmithKline executive from leaving the country as police accuse the British drugmaker of bribing officials and doctors, the drugmaker says.
U.S. stock index futures turned slightly positive Wednesday after Fed Chairman Ben Bernanke reiterated the central bank's plan to start paring back its bond-purchase program later this year, but said that could change if the economic outlook shifted.
China is using "concerted" probes of foreign baby formula, pharmaceutical and packaging companies to bolster domestic firms, according to observers.
At the heart of Illinois is Chicago, the nation’s third-largest metro area and home to world-class institutions including the Chicago Symphony and the Art Institute of Chicago.
Chinese authorities are investigating a possible price-fixing for infant formula milk, as consumers pay premiums for imported products on fears that local ones may be contaminated.
The delay of Obamacare's employer mandate isn't a blow to health-care stocks. However, the outlook for reform is another matter.
Cramer has been looking at long-term losers to see if any show potential. He’s found something.
Cramer’s convinced the best way to for this health care company to maximize shareholder value is to break up.